Cancer MoonShot 2020 Milestone: The Nation's First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer

Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for cancer care, a Cancer MoonShot 2020 milestone. 

Read More

Cancer MoonShot 2020 Milestone: NantWorks Announces NantCare Oncology Solutions, A Technology Support Platform for Community Oncology Practices in the Oncology Care Model (OCM)

NantCare, a member of the NantWorks family of companies responsible for operationalizing the Cancer MoonShot 2020 and QUILT programs, today announced its active engagement with community oncology practices by providing a combination of technology, access to clinical trials and administrative support to optimize community oncology practices’ compliance in the Oncology Care Model (OCM).

Read More

Cancer MoonShot Milestone: Announcing Launch of the Nation's Largest Pediatric Brain Tumor Atlas

NantHealth, Inc.(Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, the Chan Soon-Shiong Institute of Molecular Medicine and the collaborators of the Pediatric Cancer Moonshot 2020 today announced that they are embarking on one of the world’s most ambitious pediatric sequencing discovery projects to date. This initiative will focus on the largest killer of pediatric cancer patients today: childhood brain tumors.

Read More

Cancer MoonShot 2020 and NantHealth Launch a Global Inflammatory Breast Cancer Working Group to Investigate Personalized Immunotherapeutic Treatment Options for Rare Disease

Cancer MoonShot 2020, the nation’s most comprehensive cancer collaborative initiative, today announced the formation of the Inflammatory Breast Cancer Working Group. The team consists of physicians, researchers and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for inflammatory breast cancer (IBC)

Read More

NantHealth Announces New Expanded Coverage with Self-Insured Employers, ‎ Insurance Payers, and Health Systems for GPS Cancer Test

NantHealth, LLC announced the expanded adoption of GPS Cancer, a unique comprehensive  molecular test to help oncology care providers guide treatment strategies for cancer care, by partnering with major self-insurers that have agreed to cover the costs for their employees requiring this test. 

Read More

Dr. Patrick Soon-Shiong to Give Keynote Address and NantKwest to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest’s Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016.

Read More

Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of Novel Neo-Epitope Anitbody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

Precision Biologics will present a poster titled, “Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes” at the American Association for Cancer Research (AACR) Annual Meeting 2016.

Read More

Dr. Patrick Soon-Shiong Selected to Join the National Cancer Institute's Blue Ribbon Panel

Physician Scientist and inventor of Abraxane to participate with 28 cancer community thought leaders to help inform the scientific direction at the NCI of the National Cancer Moonshot Initiative

CULVER CITY, Calif. – April 7, 2016 ‎– The National Cancer Institute announced the selection of Patrick Soon-Shiong, M.D., FRCs (c), FACS to the Blue Ribbon Panel of scientific experts, cancer leaders and patient advocates that will inform the scientific direction and goals at the National Cancer Moonshot Institute of Vice President Joe Biden’s National Cancer Moonshot Initiative.

Dr. Soon-Shiong will be a member of the panel of experts that will provide recommendations to the National Cancer Advisory Board, which advises the NCI, on how to advance the themes that have been proposed for the initiative. The themes include the development of cancer vaccines, highly sensitive approaches to early detection, advances in immunotherapy and combination therapies, single-cell genomic profiling of cancer cells and cells in the tumor microenvironment, enhanced data sharing, and new approaches to the treatment of pediatric cancers.

The 28-member Blue Ribbon Panel brings together a group of cancer thought leaders to address opportunities in prevention, diagnosis and treatment of cancer. The panel includes extramural investigators, members of the public, cancer advocacy groups, pharmaceutical and biotechnology industries and communities with expertise in clinical trials and health disparities. 

“It’s an extremely exciting time in the history of the war against cancer— our program, Cancer MoonShot 2020, and Vice President Biden’s National Cancer Moonshot are important calls to action to urge collaboration in order to make impactful strides, accelerate progress, and win this war,” said Patrick Soon-Shiong, CEO of NantWorks and leader of the Cancer MoonShot 2020, a non-profit cancer collaborative. “It’s an honor to join the Blue Ribbon Panel and have the opportunity to share the steps we have already taken with Cancer MoonShot 2020 to accelerate immunotherapy development and drive comprehensive pan-omic precision cancer care. We are most excited by the strides we have made in engaging both community oncologists and the pediatric community in our efforts to establish a Cancer Moonshot Network to accelerate clinical trials,” he said.

Read More